Skip to content

Novavax NVAX Free cash flow

Free cash flow at other companies

Merck & Co. logo
Merck & Co.MRK
$2.93B+150%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
-$282.73M-64.7%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.68M-29.0%
ALN
Alnylam PharmaceuticalsALNY
$48.67M+138%
Moderna logo
ModernaMRNA
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%

Valuation

See full
Market cap$1.46B+28.6%
Enterprise value$1.53B+68.6%
P/S2.5×+1.5×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Calculated from Novavax’s reported figures.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's free cash flow?
Novavax (NVAX) reported free cash flow of -$33.69M in Q1 2026.
How has Novavax's free cash flow changed year-over-year?
Novavax's free cash flow increased by 82.0% year-over-year, from -$187.1M to -$33.69M.
What is the long-term trend for Novavax's free cash flow?
Over 2 years (2022 to 2024), Novavax's free cash flow has grown at a -55.4% compound annual growth rate (CAGR), from -$504.99M to -$100.32M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.